This week’s articles describe a way to enhance BH3 mimetics in cancer therapy and a method to achieve targeted delivery of miRNAs to tumors.
CANCER THERAPY
Cutting off another tumor lifeline
Merino et al. report that inhibiting the prosurvival protein MCL-1 enhances the effectiveness of conventional BH3 mimetic therapies in triple-negative and HER2-amplified breast cancer.
Fixing with folate
Orellana et al . developed a nontoxic way to deliver microRNAs directly to tumors in vivo using folate.